4-methoxy-N-(7-methyl-3-(2-pyridinyl)-1-isoquinolinyl)benzamide | 390817-85-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-methoxy-N-(7-methyl-3-(2-pyridinyl)-1-isoquinolinyl)benzamide
• 英文别名: 4-methoxy-N-(7-methyl-3-pyridin-2-ylisoquinolin-1-yl)benzamide
• CAS: 390817-85-3
• 化学式: C₂₃H₁₉N₃O₂
• 分子量: 369.4
• InChiKey: YRVCIGPJMKDQQB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  64.1
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION
  申请人：Oradin Pharmaceutical Ltd.

  公开号：EP2456419A1

  公开（公告）日：2012-05-30
• COMPOSITIONS AND METHODS OF ENHANCING SURVIVABILITY AND REDUCING INJURY OF CELLS, TISSUES, ORGANS, AND ORGANISMS UNDER HYPOXIC OR ISCHEMIC CONDITIONS
  申请人：Tomaselli James Kevin

  公开号：US20070265223A1

  公开（公告）日：2007-11-15

  The present invention provides methods, compositions, and articles of manufacture comprising adenosine, an adenosine derivative or analog, an adenosine receptor agonist, a chemical entity that is taken up by a nucleoside transporter, or a chemical entity that binds to and/or modulates a nucleoside transporter, which protect biological material from cellular or tissue damage resulting from ischemia or hypoxia, including ischemia and hypoxia due to injury, disease, or hemorrhaging. These methods, compositions, and articles of manufacture also enhance the survivability of biological material subjected to ischemia due to injury, disease, or hemorrhage.
• US9199102B2
  申请人：——

  公开号：US9199102B2

  公开（公告）日：2015-12-01
• US9668959B2
  申请人：——

  公开号：US9668959B2

  公开（公告）日：2017-06-06
• [EN] A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION<br/>[FR] LIGANDS DU RÉCEPTEUR A3 DE L’ADÉNOSINE MODULANT LA PIGMENTATION
  申请人：UNIV RAMOT

  公开号：WO2011010306A1

  公开（公告）日：2011-01-27

  The present invention relates to compositions and methods for modulating melanin production, secretion and/or accumulation in human skin cells. In particular, the present invention relates to the use of A3 adenosine receptor antagonists in compositions and methods for the treatment and amelioration of hyper-pigmentation conditions and for the lightening of skin, and to the use of A3 adenosine receptor agonists in compositions and methods for the treatment and amelioration of hypo-pigmentation conditions and for the tanning of skin.